The first clinical demonstration of the anti-tumor potential of high-dose intravenous IL-2 occurred in 1984 at the National Cancer Institute (NCI) under the direction of Dr. Steven Rosenberg when a 33-year-old woman with metastatic melanoma and extensive subcutaneous metastatic deposits underwent a dramatic inpatient treatment course at the National Institutes of Health Clinical Center. The gene discussed is IL2; the disease is metastatic melanoma.